19-06-13 Celgene Corporation Announces Update on Etigilimab Partnership CI
19-04-23 OncoMed Pharmaceuticals, Inc. Announces Executive Resignations in Connection with the Merger Agreement CI
19-04-23 OncoMed Pharmaceuticals, Inc.(NasdaqGM:OMED) dropped from NASDAQ Composite Index CI
19-04-22 Mereo BioPharma Group plc completed the acquisition of OncoMed Pharmaceuticals, Inc. from Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., MSI BVF SPV, LLC and Biotechnology Value Trading Fund OS LP managed by BVF Partners LP and others. CI
19-04-18 OncoMed Pharmaceuticals, Inc.(NasdaqGS:OMED) dropped from S&P TMI Index CI
19-03-15 OncoMed Pharmaceuticals, Inc. Declares Special Dividend of Contingent Value Rights, Payable on April 5, 2019 CI
19-03-07 OncoMed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2018 CI
18-12-06 Oncomed Pharmaceuticals, Inc. Announces Executive Changes CI
18-12-05 Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc. - M&A Call
18-12-04 Mereo BioPharma Group plc agreed to acquire OncoMed Pharmaceuticals, Inc. for $57.4 million. CI
18-11-09 OncoMed Announces Early Clinical Data for anti-TIGIT Antibody CI
18-11-01 Oncomed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Earnings Guidance for the Year 2018 CI
18-10-17 Celgene Notifies OncoMed Pharmaceuticals, Inc. of Its Decision Not to Exercise Option to License Rosmantuzumab and Subsequently Terminated the Companies’ Collaboration Agreement with Respect to Rosmantuzumab, Effective February 12, 2019 CI
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+1.07%-3.49%-3.25%+12.87% 46.35B
-0.18%+1.72%+408.79%+630.03% 40.13B
-0.20%+4.50%+9.98%+67.00% 36.33B
+0.90%+1.14%+3.88%-8.57% 34.6B
+3.14%+1.02%+3.72%+34.86% 26.77B
+0.89%-2.09% - - 16.66B
+0.63%+12.77%+33.08%+145.57% 16.91B
+0.42%-5.52%+0.76%+8.50% 13.05B
-1.66%-1.46%-14.10%-30.96% 13.05B
Average +0.46%+1.02%+55.36%+107.41% 27.09B
Weighted average by Cap. +0.61%+0.77%+75.86%+136.97%
Logo Oncomed Pharmaceuticals Inc
OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.
Employees
-